Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 436

1.

Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.

Welch HG, Albertsen PC.

J Natl Cancer Inst. 2009 Oct 7;101(19):1325-9. doi: 10.1093/jnci/djp278. Epub 2009 Aug 31.

2.

Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.

Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ.

J Natl Cancer Inst. 2002 Jul 3;94(13):981-90.

PMID:
12096083
3.

Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.

Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D, Hamdy F, Stephens P, Lane JA, Moore R, Donovan J.

Lancet Oncol. 2008 May;9(5):445-52. doi: 10.1016/S1470-2045(08)70104-9. Epub 2008 Apr 16.

4.

The role of increasing detection in the rising incidence of prostate cancer.

Potosky AL, Miller BA, Albertsen PC, Kramer BS.

JAMA. 1995 Feb 15;273(7):548-52.

PMID:
7530782
5.

Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.

Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, Ward EM.

JAMA. 2015 Nov 17;314(19):2054-61. doi: 10.1001/jama.2015.14905.

PMID:
26575061
6.

Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.

Welch HG, Schwartz LM, Woloshin S.

J Natl Cancer Inst. 2005 Aug 3;97(15):1132-7.

PMID:
16077071
7.

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.

Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.

J Natl Cancer Inst. 2009 Mar 18;101(6):374-83. doi: 10.1093/jnci/djp001. Epub 2009 Mar 10.

8.

The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States.

Legler JM, Feuer EJ, Potosky AL, Merrill RM, Kramer BS.

Cancer Causes Control. 1998 Oct;9(5):519-27.

PMID:
9934717
9.

Five-year downstream outcomes following prostate-specific antigen screening in older men.

Walter LC, Fung KZ, Kirby KA, Shi Y, Espaldon R, O'Brien S, Freedland SJ, Powell AA, Hoffman RM.

JAMA Intern Med. 2013 May 27;173(10):866-73. doi: 10.1001/jamainternmed.2013.323.

10.

Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.

Wever EM, Draisma G, Heijnsdijk EA, Roobol MJ, Boer R, Otto SJ, de Koning HJ.

J Natl Cancer Inst. 2010 Mar 3;102(5):352-5. doi: 10.1093/jnci/djp533. Epub 2010 Feb 8.

11.

Prostate cancer epidemiology in the United States.

Brawley OW.

World J Urol. 2012 Apr;30(2):195-200. doi: 10.1007/s00345-012-0824-2. Epub 2012 Apr 5. Review.

PMID:
22476558
12.

Prostate cancer screening in Tyrol, Austria: experience and results.

Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, Bartsch G.

Eur Urol. 1999;35(5-6):523-38.

PMID:
10325519
14.

Expected population impacts of discontinued prostate-specific antigen screening.

Gulati R, Tsodikov A, Etzioni R, Hunter-Merrill RA, Gore JL, Mariotto AB, Cooperberg MR.

Cancer. 2014 Nov 15;120(22):3519-26. doi: 10.1002/cncr.28932. Epub 2014 Jul 25.

15.
16.
17.

The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.

Culp S, Porter M.

BJU Int. 2009 Nov;104(10):1457-61. doi: 10.1111/j.1464-410X.2009.08646.x. Epub 2009 Jun 12.

18.
19.

Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.

Tonita JM, Skarsgard D, Muhajarine N.

Cancer Causes Control. 2009 Mar;20(2):201-9. doi: 10.1007/s10552-008-9234-6. Epub 2008 Sep 30.

PMID:
18825504
20.

Unanswered questions in screening for prostate cancer.

Neal DE, Leung HY, Powell PH, Hamdy FC, Donovan JL.

Eur J Cancer. 2000 Jun;36(10):1316-21. Review.

PMID:
10882874

Supplemental Content

Support Center